Ionis Pharmaceuticals, Inc.
IONS
$43.03
$0.050.12%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 16.05% | -7.64% | -10.48% | 30.57% | 29.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 16.05% | -7.64% | -10.48% | 30.57% | 29.00% |
| Cost of Revenue | -2.84% | -3.00% | -0.34% | -4.70% | -1.66% |
| Gross Profit | 157.84% | -22.36% | -65.56% | 67.38% | 66.66% |
| SG&A Expenses | 31.76% | 31.53% | 29.14% | 13.34% | 41.26% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.50% | 3.84% | 5.25% | -1.47% | 5.11% |
| Operating Income | 22.75% | -28.00% | -42.36% | 36.94% | 26.83% |
| Income Before Tax | 22.15% | -27.60% | -37.76% | 5.25% | -25.25% |
| Income Tax Expenses | -146.95% | -129.17% | -119.10% | -91.12% | -52.05% |
| Earnings from Continuing Operations | 26.67% | -19.04% | -23.92% | 12.37% | -18.35% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 26.67% | -19.04% | -23.92% | 12.37% | -18.35% |
| EBIT | 22.75% | -28.00% | -42.36% | 36.94% | 26.83% |
| EBITDA | 23.22% | -29.36% | -44.33% | 37.69% | 27.28% |
| EPS Basic | 30.58% | -11.81% | -18.79% | 14.66% | -16.65% |
| Normalized Basic EPS | 27.11% | -24.57% | -40.45% | 39.68% | 27.98% |
| EPS Diluted | 27.55% | -11.81% | -18.79% | 14.66% | -16.65% |
| Normalized Diluted EPS | 22.12% | -24.57% | -40.45% | 39.68% | 27.98% |
| Average Basic Shares Outstanding | 7.89% | 6.13% | 4.35% | 2.27% | 1.58% |
| Average Diluted Shares Outstanding | 11.89% | 6.13% | 4.35% | 2.27% | 1.58% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |